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Abstract 
The aim of this study was m establish whether or not al-adrenergic receptors are implicated in triggering phosphoinositide hydrolysis 
and intracelhilar Ca 2+ accumulation during myocardial ischemia nd reperfusion. In isolated perfused rat hearts, the selective avreceptor 
antagonist prazosin abolished the increase in radioactivity incorporation i to cellular inositol phosphates induced by 30 min ischemia 
followed by 30 min reperfusion, and selectively blocked the degradation of phosphoinositides; only minor changes in the ischemia/reper- 
fusion-induced loss of other classes of phospholipids were seen. In addition, a prazosin-induced decrease of ischemia/reperfusion Ca 2+ 
overloading was documented in real-time recordings of epicardial cytosolic free Ca 2+ in fura 2-10aded hearts. An inhibition of early 
ischemic Ca 2+ rise was observed, as well as a lower peak of cytosolic free Ca 2+ and a more rapid reversal to normal values during 
reperfusion. Moreover, a l-adrenergic blockade resulted in a significant improvement in the recovery of myocardial function during 
reperfusion: an increased left ventricular developed pressure and maximum rate of rise of systolic pressure paralleled the decrease in 
time-averaged cytosolic Ca 2+ and the increase in amplitude of Ca 2+ transients, respectively. It is concluded that myocardial Ca 2+ 
overloading during ischemia nd reperfusion may be triggered by aradrenergic receptor-induced polyphosphoinositide hydrolysis. 
Keywords: Alpha adrenergic receptor; Calcium; Phospholipase C; Phosphoinositide; Myocardial reperfusion i jury 
I. Introduction 
A pronounced isturbance in intracellular Ca 2+ home- 
ostasis is a major subcellular pathophysiological feature of 
myocardial reversible ischemia and reperfusion, resulting 
in an increase in intracellular Ca 2+ (i.e., Ca 2÷ 'overload- 
ing') with significant contribution to post-ischemic con- 
tractile dysfunction. However, the extent, the mechanism, 
and the time course of Ca 2+ overloading is a matter of 
dispute, since different investigative approaches have gen- 
erated conflicting results - for reviews see Refs. [1,2]. 
Abbreviations: PLC, phospholipase C; PLA 2, phospholipase A2; 
KHB, Krebs-Henseleit buffer; EGTA, [Ethylene- 
bis(oxythylenenitrilo)]tetraacetic id; FAME, fatty acid methyl esters; 
fura-2 AM, fura-2 acetoxymethyl ester; LVDP, left ventricular developed 
pressure; LV dp/dtma x, maximum rate of rise of left ventricular pres- 
sure. 
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Signaling through phosphoinositide breakdown is now 
well-known for regulating cytosolic Ca 2÷ levels in a vari- 
ety of tissues through inositol phosphate generation [3]; 
however, in myocytes, the action of inositol phosphates i
another controversial issue [4-6]; even the existence of the 
intracellular receptor for inositol 1,4,5-trisphosphate has 
only been very recently reported [7,8]. 
In this study we attempted to document a causal link 
between al-adrenergic receptor activity, phosphoinositide 
signaling, and intracellular Ca 2 ÷ overloading. The elucida- 
tion of these mechanisms may have considerable clinical 
and pharmacological significance, since %-receptor antag- 
onists, such as prazosin, were shown in some early studies 
[9,10] to have potential beneficial effects on post-ischemic 
myocardial contractility. 
We have previously reported that myocardial ischemia 
and reperfusion i duce an enhanced phospholipase C (PLC) 
activity, which may contribute to cell injury [11]. Recently, 
we have developed a technique to record real-time free 
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cytosolic Ca 2 + from left ventricular epicardium of whole 
perfused rat hearts [12], which has raised new questions 
about the mechanisms of disturbances of Ca 2+ homeosta- 
sis during ischemia nd reperfusion. We have shown that 
in a reversible ischemic insult, in contrast o total tissue 
Ca 2+ accumulation, free cytosolic Ca 2+ rises from the 
beginning of ischemia and after peaking at the onset of 
reperfusion it slowly declines. Several different lines of 
evidence suggest that al-adrenergic receptors may be 
crucially involved in these phenomena. First, a l-adren- 
ergic receptors have been shown to be coupled to the 
phosphoinositide signaling system in the heart [13-16]. 
Second, al-agonists appear to increase cytosolic Ca 2+ in 
the normal heart, presumably as a result of inositol phos- 
phate generation [17-19]. Third, although the density and 
affinity of C~l-receptors does not seem to be influenced by 
ischemia nd reperfusion i  the rat heart [20,21], myocytes 
exposed to hypoxia show a rapid increase in the sensitivity 
of phosphoinositide hydrolysis in response to C~l-agonists 
[22,23], which are known to be released uring ischemia in 
myocardial tissue [24]. A significant portion of ischemic 
adrenergic stimulation is due to locally released mediators 
[25,26], which makes it possible to use isolated perfused 
heart setups to study not only the effect of adrenergic 
agonists but also of antagonists. 
Here we have tested the hypothesis that c~l-receptor 
stimulation is the cause of ischemia/reperfusion enhanced 
PLC activity, and that this signaling pathway is involved in 
inducing increased cellular Ca 2+ accumulation, using de- 
tailed measurement of phospholipid metabolism during 
ischemia nd reperfusion of the isolated perfused rat heart 
in the absence or presence of an al-receptor antagonist 
(prazosin). We have further examined how prazosin-in- 
duced changes in phosphoinositide metabolism relate to 
cytosolic free Ca 2+ levels and left ventricular functional 
parameters during ischemia nd repeffusion. 
2. Materials and methods 
2.1. Heart perfusion model 
Sprague-Dawley rats weighing 300-350 g were anes- 
thetized with 250 mg/kg intraperitoneal sodium pento- 
barbital and the hearts were isolated and perfused on a 
Langendorf setup as described previously [27,28]. After 
equilibration, in the case of isotopic studies, hearts were 
labeled by 45 min perfusion with 50 ml recirculating 
Krebs-Henseleit buffer (containing 3% bovine serum albu- 
min; pH 7.4) (KHB) containing 80 /~Ci myo-[3H]inositol 
and 5 mM LiCI (for inositol phosphate measurements) or 2 
/zCi of [1-14C]arachidonic a id (for phospholipid etermi- 
nations) followed by a 10-min washout perfusion. After 10 
min of perfusion with KHB containing 1 /xM prazosin, 
hearts were subjected to 30 min normothermic global 
ischemia by terminating the retrograde aortic flow, fol- 
lowed by 30 min of normoxic reperfusion (with KHB 
containing 5 mM LiC1 in the inositol phosphate measure- 
ment experiments). For control experiments, after the same 
labeling, hearts were perfused with normal KHB for 10 
min followed by the same ischemia nd reperfusion proto- 
col, and baseline hearts were perfused normoxically for 70 
min. At the end of all experiments, hearts were sectioned 
at the atrio-ventricular junction and the ventricular muscle 
was frozen in liquid nitrogen and stored at -89  ° C. For 
left ventricular pressure recordings, a balloon-tipped 
catheter was introduced through the left atrium into the left 
ventricle in hearts ubjected to 10 min prazosin or drug-free 
(control) perfusion (post-equilibration), 30 min global is- 
chemia, and 30 min reperfusion, or 70 min normoxic 
perfusion (baseline). The compliant latex balloon was filled 
with saline and the volume adjusted to produce an 8-10 
mmHg end-diastolic pressure under baseline conditions, 
and connected to a Statham P23 I.D. pressure transducer 
coupled to a Honeywell AR-6 polygraph recorder (PPG 
Biochemical Systems, Honeywell, Pleasantville, New 
York). Pressure readings as well as dp/dt  (real-time 
signal obtained through integrated electronic differentia- 
tion) recordings were taken prior to ischemia nd at vari- 
ous time points during reperfusion. 
2.2. Inositol phosphate determination 
400-600 mg of frozen ventricular tissue was homoge- 
nized in 10% trichloroacetic a id, 5 mM EDTA, and 5 mM 
phytic acid (to reduce non-specific adsorption of inositol 
polyphosphates in the precipitate). The precipitate was 
then re-extracted once, and the pooled supernatants were 
neutralized with 6 N KOH. After centrifugation at6,000 × 
g, the inositol phosphate-containing supernatants (3 ml) 
were applied to 1 ml ion-exchange chromatography 
columns (Dowex type analytical grade AG l-X8, 100-200 
mesh, formate form; Bio-Rad Laboratories, Melville, NY) 
and the inositol phosphate fractions were eluted through 
stepwise buffer changes according to a modified method of 
Berridge et al. [29]. Briefly, after eluting with 10 ml H20 
and 5 ml 5 mM borax/60 mM sodium formate, four 
elutions with 15 ml 0.1 M formic acid/0.2-0.4-1.0 M
ammonium formate were performed to collect inositol 
monophosphates, bisphosphates, and Tris- and tetrakispho- 
sphates, respectively. Radioactivity of individual fractions 
was then measured by liquid scintillation counting. 
2.3. Phospholipid etermination 
Lipids were extracted from 200-400 mg fragments of 
the frozen [14C]arachidonic acid-labeled hearts by the mod- 
ified method of Folch et al. [30] as described by Shaikh 
and Downar [31], using 0.005% butylated hydroxytoluene 
as an antioxidant during the extraction. The dried extract 
was solubilized in 200/zl chloroform/methanol (1:1 v/v),  
and 25-/xl aliquots were used for separation of individual 
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phospholipid fractions by thin layer chromatography on 
silica gel K6 (for individual classes of phospholipids), 
using chloroform:petroleum ether:methanol:acetic 
acid:boric acid 40:30:20:8:1.8 (v /v /v /v /w)  as migrating 
solvent, and on silica gel G plates (for separation of total 
phospholipids and diacylglycerol) using petroleum 
ether:diethyl ether:acetic acid 80:20:1 (v /v /v )  as migrat- 
ing solvent. The radioactivity incorporated into each frac- 
tion as well as of an aliquot of the total lipid extract (to 
standardize the results with regard to individual differences 
in the hearts uptake of [1-14C]arachidonic a id) was then 
measured. 
Determinations of phosphoinositide mass were carried 
out using a modification of a previously described method 
[32]. In separate perfusion experiments hearts were not 
radioactively abeled. After extraction of lipids and separa- 
tion of phospholipid classes by thin layer chromatography 
as described above, the phosphoinositide spot was scraped 
into 0.5-ml anhydrous methanol containing 0.05% BHT, 
and then 0.5 ml of 20% acetylchloride in methanol was 
added to the mixture. Afl:er heating at 90-100°C for 90 
min in a water bath, the test tubes were cooled and the 
methanolyzate n utralized with excess anhydrous Na2CO 3. 
The fatty acid methyl ester (FAME) derivatives of acyl 
groups were extracted with 2 ml hexane and 0.6 ml 
saturated aqueous NaC1. The hexane phase was removed, 
pooled with the hexane phase of a re-extraction, and the 
volume reduced by evaporation under a stream of N 2. One 
/xl of the FAME-containing hexane was then analyzed by 
gas chromatography (HP 5890A, Hewlett Packard, Avon- 
dale, PA) on a Supelco SP-2330 30 m polar phase capil- 
lary column (Supelco, Bellefonte, PA). Individual FAME 
were identified by elution times of standards and equiva- 
lent chain length, and quantitation of peak areas was 
standardized with respect to odd-chain length internal stan- 
dards. 
2.4. Phospholipase assay 
Microsomal PLA 2 and PLC activities were measured as 
described previously [11]. Briefly, subcellular fractions of 
ventricular muscle biopsies (homogenized in 0.25 M su- 
crose, 10 mM Hepes, 1 mM EGTA, 0.02% nagarase, pH 
7.5) were isolated as described [27,28] and aliquots of 
microsomal and cytosolic fractions containing 300 /zg 
protein (BCA protein assay, Pierce, Rockford, IL) were 
incubated for 60 min at 377 °C in a final volume of 0.8 ml 
of 10 mM, Tris/HC1 buffer (pH 7.4), containing 1 mM 
CaC12 and 20 /xM L-a-l-palmitoyl-2-arachidonyl- 
phosphatidylcholine with [l-~4C]arachidonyl-phosphatidyl - 
choline tracer (45,000 cpm). The reaction was stopped by 
addition of 3 ml chloroform/methanol (1:2 v /v)  and 
lipids extracted by the method of Bligh and Dyer [30]. 
Total phospholipids, free fatty acids, and diglycerides were 
then separated by thin layer chromatography on silica gel 
G plates as described above. PLA 2 and PLC activities 
were calculated from the radioactivity present in free fatty 
acids and diacylglycerols, respectively. Phosphoinositide- 
specific PLC activity was measured as production of 
[3H]inositol 1,4,5-trisphosphate from phosphatidyl[2- 
3H]inositol 4,5-bisphosphate as previously described [33]. 
Briefly, microsomal fractions were incubated for 60 min at 
37°C in 50 mM Hepes pH 7.4, 1 mM EDTA, 0.05% 
sodium deoxycholate with the addition of CaCi2 to obtain 
a free Ca 2+ concentration f 1 /xM. A concentration f 20 
/xM phosphatidyl[2-3H]inositol 4,5-bisphosphate was used 
as substrate and radioactivity in the upper (aqueous) phase 
of an organic extraction (containing the [3H]inositol 1,4,5- 
trisphosphate produced) was measured by liquid scintilla- 
tion counting. 
2.5. Cytosolic Ca 2 + measurement 
The cytosolic free Ca 2+ was measured in a separate 
perfusion setup as follows: Fura 2 acetoxymethyl ester 
(fura 2-AM) was solubilized in 3:1 (v/v)  dimethylsulf- 
oxide/Cremophor EL (2.5%), 0.1 ml of which was added 
to 50 ml of KHB to give a final concentration f 0.5 /zM 
fura 2-AM. Isolated rat hearts in a Langendorff model 
were perfused after equilibration with recirculating KHB 
containing fura 2-AM for 15 min followed by a 15-min 
washout perfusion. The heart perfusion chamber was then 
changed to a thermostatic chamber of a calcium analyzer 
(CAF-100, Jasco, Baltimore, MD) equipped with a dual 
wavelength spectrofluorimeter fo exciting and detecting 
fura 2 fluorescence. Fluorescence excitation was provided 
by a Xenon lamp. Illumination passed through a filter 
wheel operated at 48 revolutions/s which has two trans- 
missive sectors, one that transmits primarily 340 nm light 
and another 380 nm light (each with a band pass of 11 
nm). The excitation light was diverted onto a circular 
region of the left ventricular epicardium of 1 cm diameter 
via a dichroic mirror. Fluorescence emission passed through 
a 500-nm wavelength filter (band pass of 12 nm) to reach 
a photomultiplier, and the signal was electronically pro- 
cessed to display the ratio of fluorescence at the two 
excitation wavelengths (F34o/F38 O) on a strip chart recorder 
with simultaneous monitoring of the electrocardiogram 
(using two epicardial electrodes). Intracellular Ca 2÷ was 
recorded continuously throughout 10 min prazosin or 
drug-free perfusion, 30 min ischemia, and 30 min reperfu- 
sion. 
2.6. Statistical analysis 
The data was analyzed using a software package for 
statistical analysis for IBM PC-compatible computers 
(Primer, McGraw and Hill, 1988). Comparison between 
two different groups was made using Student's unpaired 
t-test, and where necessary, multiple analysis of variance 
followed by the Bonferroni correction was used. 
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3. Results 
3.1. lschemia / reperfusion phosphoinositide signaling 
A number of recent studies suggest hat stimulation of 
myocardial a l-receptors activates the phosphoinositide 
signal transduction pathway [13-16,18,34]. We have pre- 
viously shown that myocardial ischemia and reperfusion 
are accompanied by an enhanced PLC enzymatic activity 
which contributes to cell injury [11]. To establish if a,-re- 
ceptors are instrumental in triggering this pathological 
increase in PLC activity, we have used the highly selective 
al-adrenergic antagonist prazosin in a perfused isolated rat 
heart model to block the putative a,-receptor signaling 
during ischemia and reperfusion. Fig. 1A shows that 10 
min pre-perfusion of hearts with 1 /xM prazosin abolished 
the ischemia/reperfusion-induced increase in accumula- 
tion of cellular inositol phosphates. In hearts subjected to 
30 rain of ischemia followed by 30 min of reperfusion in 
the presence of 5 mM LiC1, both the cytosolic total inositol 
phosphates and the inositol trisphosphate fraction had ap- 
proximately 3-fold higher levels as compared to those in 
normoxically perfused hearts. Our technique cannot distin- 
guish between the active inositol 1,4,5-trisphosphate and 
its inactive isomer, inositol 1,3,4-trisphosphate, and thus 
the actual degree of changes in inositol 1,4,5-trisphosphate 
may be different han those in the total inositol trisphos- 
phate fraction. Most of the production of inositol phos- 
phates apparently can be accounted for during the first 10 
min of ischemia (Fig. 1A). In hearts exposed to prazosin, 
no statistically significant increase in inositol phosphates 
was present during ischemia and reperfusion. Assay of 
microsomal PLC activity using phosphatidylcholine as 
substrate also showed a significant reduction (more than 
50%) of the ischemia/reperfusion-induced increase in en- 
zymatic activity (Fig. 1 B) in prazosin-treated hearts. How- 
ever, in contrast o the total abolishment of inositol phos- 
phate increase over baseline levels, PLC activity in the 
presence of ce~-adrenergic blockade was still significantly 
higher than baseline values at the end of reperfusion. In 
contrast, the increase in phosphoinositide-specific PLC 
activity was virtually eliminated by prazosin. While both 
PLC and PLA 2 activities contribute to the ischemia/reper- 
fusion-induced loss of membrane phospholipids, it appears 
that in the case of PLC two types of activities may be 
involved: one phosphoinositide-specific triggered by ce,- 
stimulation, and the other one phosphatidylcholine- 
preferring and (partially) a,-receptor independent. To see 
if prazosin selectively blocks PLC-catalyzed hydrolysis of 
phosphoinositides, we have performed detailed measure- 
ments of membrane lipid composition alterations during 
ischemia and reperfusion. Table 1 shows that prazosin 
(which appeared not to affect PLA 2 activity - Fig. I B) 
almost completely eliminated the loss of phosphatidyl- 
inositol lipids during ischemia and reperfusion, but had 
less effect on the degradation of phosphatidylcholine and 
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Fig. 1. (A) Effect of c~l-adrenergic blockade on myocardial inositol 
phosphate g neration. Rat hearts pre-labeled with [3H]myo-inositol were 
subjected to either 70 min normal perfusion (Baseline), or 10 min 
drug-free (Control) or 1 /zM prazosin (Prazosin) perfusion followed by 
30 min global ischemia nd 30 min reperfusion. Radioactivity incorpo- 
rated into total cellular inositol phosphates (InsPs) as well as into the 
inositol trisphosphate fraction (InsP 3) was quantitated from frozen ven- 
tricular muscle biopsies taken at the end of the experiment (Isch/Reperf) 
or after l0 min of ischemia (I0' Ischemia). Results are expressed as 
mean + S.E.M. of six separate experiments; statistical significant differ- 
ences between treated and control groups (x) and between ischemia/re- 
perfusion and baseline values (* ) were determined byanalysis of vari- 
ance followed by Bonferroni's t-test. (B) Effect of oq-adrenergic block- 
ade on myocardial phospholipase activities. Microsomal fractions ob- 
tained from biopsies of hearts ubjected tothe same perfusion protocols 
as in panel A taken after 10 min ischemia were assayed for phosphatidyl- 
choline-preferring PLC (PC-PLC) and PLA 2 activity using [1- 
~4C]arachidonoyl-phosphatidylcholine as substrate, and for phosphoinosi- 
tide-specific PLC activity (PI-PLC) using phosphatidyl[2-3H]inositol 4,5- 
bisphosphate as substrate. Statistical nalysis of the results was performed 
as described inpanel A. 
of other classes of phospholipids. Although the enhanced 
PLA:  activity might interfere with the measurements based 
on ['4C]arachidonic acid incorporation into membrane 
lipids, these results were not artifacts of disturbed arachi- 
donic acid metabolism, since mass determination of phos- 
pholipid content by post-thin layer chromatography deriva- 
tization followed by gas chromatography ave confirmed 
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the restoring effect of prazosin on reperfusion levels of 
inositol phospholipids as well as the less pronounced effect 
on phosphatidylcholine (Table 2). These data agree well 
with those in Fig. 1A (regarding inositol phosphates) as 
well as with the only partial reduction by prazosin of 
ischemia/reperfusion-induced increase of diacylglycerol 
(Table 1) (see Discussion). Taken together, the above 
results uggest that C~l-adrenergic receptor blockade results 
in a selective inhibition of PLC-catalyzed breakdown of 
phosphoinositides during ischemia nd reperfusion. 
3.2. Effect of prazosin on cytosolic free Ca 2 + and myocar- 
dial postischemic functional recovery 
One of the major contributing mechanisms tocell injury 
during myocardial ischemia and reperfusion is the intra- 
cellular Ca 2÷ overloading [1,2]. Although the role of phos- 
phoinositide signaling, and in particular the role of inositol 
1,4,5-trisphosphate, in intracellular Ca 2+ homeostasis i
still a matter of controversy [4-6,35], a large body of 
evidence points toward a]-adrenergic receptor-triggered 
phosphoinositide hydrolysis as having a significant effect 
of increasing cytosolic Ca 2+ levels, partly accounting for 
the positive inotropic response elicited by al-agonists 
[18,36]. We therefore tested the hypothesis that the above 
documented al-receptor-mediated increase in phospho- 
inositide hydrolysis during myocardial ischemia nd reper- 
fusion may be a major contributing mechanism to Ca 2÷ 
overloading and thus to cellular injury. Using a Jasco 
CAF-100 Ca 2÷ spectrofluorimeter equipped with an organ 
bath, we have been able to obtain real-time recordings of 
epicardial cytosolic free Ca 2+ in intact isolated perfused 
rat hearts loaded with fura 2 [12]. Fig. 2 shows typical 
recordings of cytosolic free Ca 2+ (expressed as ratio of 
fura 2 fuorescence at 340 nm and 380 nm excitation 
wavelengths) of an untreated and a prazosin-treated heart 
during a 70-min time interval (10 min drug perfusion, 30 
min ischemia, 30 min reperfusion) after loading with fura 
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Fig. 3. Effect of oq-adrenergic blockade on post-ischemic myocardial 
contractility. Left ventricular developed pressure (LVDP - panel A) and 
the maximum rate of rise of left ventricular systolic pressure (LV 
dp/dtma x - panel B) were measured after equilibration (Baseline), after 
l0 min of drug or drug-free perfusion (Pre-I), and at 15 min (I5'R) and 
30 min (30'R) of reperfusion which followed a 30 min period of global 
ischemia. Results are expressed as mean 4-S.E.M. of minimum six sepa- 
rate experiments. Analysis of variance was performed to establish statisti- 
cal significant differences between treated and control groups (*)  and 
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Fig. 2. Intracellular f ee Ca 2+ levels during ischemia nd reperfusion of 
prazosin-treated and untreated hearts. Electronically integrated ratio of 
fluorescence (500 nm) at 340 nm and 380 nm excitation wavelengths 
(F340/F3s 0) was continuously recorded uring drug (1 /~M prazosin) or 
drug-free perfusion (first 10 min in figure), and during ensuing 30 min of 
global ischemia nd 30 rain of reperfusion. The figure shows two typical 
recordings of separate xperiments. 
effect on either the time-averaged Ca 2+ concentration or
the amplitude of the Ca 2+ transients in the normoxically 
perfused heart (first 10 min of the recording), it both 
lowered the average Ca 2+ concentration during ischemia 
and the amplitude of the transients during the first few 
minutes of ischemia (before the heart stops). Moreover, 
while after 30 min of reperfusion control hearts did not 
exhibit a full return of cytosolic Ca 2+ to normal evels, in 
the presence of a~-receptor blockade, hearts showed al- 
most normal evels of cytosolic free Ca 2+ after 20-25 min 
of reperfusion, and, apparently paradoxical, a higher ampli- 
tude of the transients at the end of reperfusion (Fig. 2). In 
order to verify that these effects of prazosin are paralleled 
by a lesser degree of functional injury, we have performed 
measurements of left intraventricular p essure at various 
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time points, prior to ischemia nd during reperfusion (Fig. 
3). No changes in left ventricular developed pressure 
(LVDP; Fig. 3A) and maximum rate of rise of left ventric- 
ular systolic pressure (LV dp/dtmax; Fig. 3B) were seen 
in pre-ischemia in the prazosin-treated hearts; however, 
both LVDP and LV dp/dtma x were significantly higher at 
all time points during reperfusion in the prazosin-treated 
hearts as compared to ischemic and reperfused controls, 
with a return to close to normal values after 30 min of 
reperfusion (while mean values were still lower for both 
LVDP and LV dp/dtma x when compared to those of 70 
min normoxically perfused hearts, this difference was not 
statistically significant: P = 0.097 and P = 0.142, respec- 
tively - results not shown). 
4. Discussion 
Myocardial Ctl-adrenergic receptors are now well known 
as having a positive inotropic effect, at least on the normal 
heart [18,34]. The fact that al-stimulation produces an 
increase in phosphoinositide metabolism in a variety of 
tissues, including the myocardium [13,15,16], has led to 
the hypothesis that inositol phosphates, most notably inosi- 
tol 1,4,5-trisphosphate, may be the mediator of such in- 
otropic effect, presumably through the increase in cytosolic 
Ca 2+ [17,19,37]. Since we and others have previously 
shown that myocardial reversible ischemia and ensuing 
reperfusion elicits an enhanced PLC activity and inositol 
phosphate generation [11,27,38], we have attempted in this 
study to verify the hypothesis that ~1-adrenergic receptors 
might be the triggering factor for myocardial ischemic 
PLC activity and that this may account at least in part for 
intracellular Ca 2+ overloading which occurs during is- 
chemia and reperfusion. 
In our perfused rat heart model of global ischemia nd 
reperfusion, we have consistently been able to obtain 
reproducible results regarding both induction of cellular 
injury as well as postischemic functional recovery 
[11,26,39]. Prazosin (1 /zM) was chosen as a highly 
selective antagonist of ce~-adrenergic receptors, producing 
a virtually complete blockade of both high and low affinity 
al-receptors [40]. The ability of prazosin to completely 
block ischemia/reperfusion-induced increase in inositol 
phosphate production (Fig. 1A) suggests that a l-receptor 
stimulation is the probable triggering factor of ischemic 
and postischemic PLC-catalyzed breakdown of phospho- 
inositides. Moreover, the simultaneous prevention of mem- 
brane phosphoinositide loss (Tables 1 and 2) suggests that 
phosphoinositides are a target only for PLC activity during 
ischemia nd reperfusion, since we have previously shown 
that PLA 2 and phospholipase D activities are also en- 
hanced by ischemia and reperfusion [11,39,41]. Phospho- 
inositide-specific PLC activity present in subcellular frac- 
tions was inhibited by prazosin as expected, but phospha- 
tidylcholine-preferring PLC activity was only partially af- 
Table 1 
Effect of prazosin on radioactivity incorporation into individual phospho- 
lipid fractions in [1-14C]arachidonic a id-labeled hearts 
Non-ischemic Control Prazosin 
Phosphoinositides 692 ±44 334_+51 b 638 ±49 " 
Phosphatidylserine 163_+ 15 88±27 b 97±26 b 
Phosphatidylethanolamine 887±51 407±79 b 501 _+43 b 
Phosphatidylcholine 4920± 184 2240±231 b 31604-244 ~,.b 
Diacylglycerol 8.9±0.9 24.6±2.7 ~ 19.0± 1.4 a.b 
After 45 min labeling with [l-14C]arachidonic a id, isolated rat hearts 
were subjected to 30 min ischemia and 30 min reperfusion without 
(control) or with (prazosin) 10 min pre-perfusion with 1 /xM prazosin, or 
to 70 min normal perfusion; after extraction of lipids from ventricular 
muscle biopsies, individual classes of phospholipids and neutral lipids 
were separated by thin layer chromatography (see Section 2). Prazosin 
completely reverses the loss of phosphoinositides (no statistically signifi- 
cant difference from non-ischemic values) while having less or no effect 
on the loss of other phospholipids; also note the partial reduction in 
ischemia/reperfusion-generated increase in diacylglycerol by prazosin. 
Results are expressed as mean iS.E.M, of six separate experiments. 
Values are cpm/g wet weight. 
P < 0.05 as compared to control and b p < 0.05 as compared to non- 
ischemic (multiple analysis of variance followed by Bonferroni's t-test). 
fected (Fig. 1B). While such in vitro assays of PLC 
activity most probably do not accurately reflect in vivo 
substrate specific±ties and enzyme activities, there seem to 
be reasons to believe that at least two different PLC 
activities are stimulated uring ischemia and reperfusion, 
one being relatively selective to phosphoinositide hydroly- 
sis, and the other(s) acting on phosphatidylcholine and 
other phospholipids. Data in Table 1 show that prazosin 
has a small inhibitory effect also on the loss of some other 
classes of phospholipids, but to a lesser extent than the 
inhibition achieved by inhibitory polyclonal anti-PLC anti- 
bodies [11]. The existence of an enhanced non-phospho- 
inositide-preferring PLC activity in the ischemic heart may 
help explaining the little effect of oq-blockade on the 
increased iacyiglycerol generation (Table 1), together with 
Table 2 
Effect of prazosin on myocardial phosphoinositide content measured by 
mass quantitation of fatty acid composition 
Non-ischemic Control Prazosin 
Phosphoinositides 874 + 20.5 647 ± 14.7 b 836 ± 47.2 a 
Palmitate content 327± 19 .3  266±6.7 b 366+25.7 ~ 
Arachidonate content 302± 13 .4  232±3.5 b 285+ 13.3 ~ 
Non-radioactively abeled hearts were subjected to the same perfusion 
protocol and lipid analysis as in Table 1. The acid methanolyzate of the 
total phosphoinositide fraction was subjected to gas chromatography for
separation and quantitation of fatty acid methyl esters (see Section 2). 
The first line shows quantitation of the phosphoinositide class by summa- 
tion of values for all component fatty acids; individual changes in two 
major types of fatty acids are also shown. Values in prazosin-treated 
hearts are not statistically significantly different from values in non- 
ischemic hearts. Results are expressed as mean+ S.E.M. of six separate 
experiments. Values are nmoles/g wet weight. 
P < 0.05 as compared to control and b p < 0.05 as compared to non- 
ischemic (multiple analysis of variance followed by Bonferroni's t-test). 
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the fact that a significant amount of diacylglycerol is 
produced indirectly during ischemia nd reperfusion from 
phosphatidic acid generated by enhanced phospholipase D.
The quantitatively minor contribution of al-receptor activ- 
ity to phospholipid egradation (except phosphoinositides) 
and diacylglycerol production during myocardial ischemia 
and reperfusion suggest hat the specific contribution of 
al-receptor activity to cell injury induced by ischemia/re- 
perfusion, if any, should be consequent to phosphoinosi- 
tide signaling through the production of inositol phos- 
phates. 
The possible effect of %-triggered inositol phosphate 
generation is an increase in cytosolic free Ca 2+. A number 
of different studies have shown that one of the major 
metabolic disturbances induced by myocardial reversible 
ischemia followed by reperfusion is the intracellular Ca 2÷ 
accumulation (Ca 2+ 'overloading') [1,2]. However, the 
time course of the increase in intracellular Ca 2+, the effect 
on cytosolic free Ca 2+ levels, and the underlying molecu- 
lar mechanisms are controversial. Data obtained by mea- 
suring total tissue and total cell Ca 2+ are somewhat ques- 
tionable (due to the lack of rapid, high yield, washout 
methods of extracellular Ca 2+ and to the fact that these 
data do not pertain to free cytosolic Ca 2÷ ), and fluorescent 
dye labeling experiments were generally limited to cul- 
tured myocytes, with the inherent drawbacks related to 
physiological relevance of the results with regard to in 
vivo conditions. Our recent data on the real-time measure- 
ments of cytosolic free Ca 2÷ throughout ischemia and 
reperfusion i isolated intact perfused rat hearts [ 12] showed 
that, immediately after the onset of ischemia (1-2 min), 
there is a rapid and significant increase in free cytosolic 
Ca 2+, which quickly reaches a plateau; reperfusion does 
trigger a small peak but without any further major increase 
in Ca 2÷, leading eventually to a gradual reversal of Ca 2+ 
concentration to lower levels. Here we have monitored the 
effect of cq-receptor blockade on free Ca 2÷ concentrations 
throughout 30 min ischemia and reperfusion (Fig. 2). 
Prazosin significantly altered the pattern of changes in 
Ca 2÷ concentration. First, it lowered the peak level of 
Ca 2÷ attained after 30 rain of ischemia and the rapid 
increase during early ischemia; this correlates very well 
with the data in Fig. 1 A showing the rapid generation of 
inositol phosphates by ischemia, a phenomenon which is 
blocked by prazosin. This suggests that the rapid increase 
in cytosolic Ca 2+ may be mediated by the rapidly acting 
second messengers, inositol phosphates. A more gradual 
increase in cytosolic free Ca 2+ was still observed uring 
ischemia in the presence of the al-adrenergic blocker. 
This may be explained by a variety of mechanisms, includ- 
ing possible protein kinase C-mediated phosphorylation f 
Ca 2÷ channels or related regulatory proteins (since pra- 
zosin did not significantly affect the ischemia-induced 
increase in diacylglycerol - Table 1). Second, free Ca 2÷ 
levels reversed much faster during reperfusion, all the way 
to baseline values. Since prazosin was previously reported 
to reduce total Ca 2+ accumulation, it appears that ol l- 
stimulated generation of inositol phosphates may be re- 
sponsible for the observed changes in Ca 2+ homeostasis 
during ischemia, which could contribute to the eventual 
deterioration of Ca 2 + control during reperfusion leading to 
the actual Ca 2+ 'overloading'. Measurements of left intra- 
ventricular pressure (Fig. 3), which show the protective 
effect of prazosin against ischemic insult as expressed by 
enhanced functional recovery during reperfusion correlate 
well with the pattern of the changes in free Ca 2 + home- 
ostasis during reperfusion: after the first few minutes of 
reperfusion, the increase in LVDP paralleled the decrease 
in time-averaged Ca2+ concentration, while the increase in 
LV dp/dtma x paralleled the increase of the amplitude of 
Ca 2 + transients. 
Therefore, we conclude that c~-receptor activity during 
myocardial ischemia and reperfusion triggers enhanced 
phosphoinositide-specific PLC activity with inositol phos- 
phate generation, which in turn may contribute to the 
elevated free cytosolic Ca 2+ levels and Ca 2+ overloading. 
This pathway can be pharmacologically inhibited by a~-re- 
ceptor antagonists with beneficial effects on post-ischemic 
myocardial function. 
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